Company Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform.
The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers.
The company was incorporated in 2014 and is based in Copenhagen, Denmark.
| Country | DK |
| IPO Date | Nov 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Dr. Qasim Iftikhar Ahmad M.D. |
Contact Details
Address: Ole Maaløes Vej 3 Copenhagen, DK | |
| Website | https://www.iobiotech.com |
Stock Details
| Ticker Symbol | IOBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001865494 |
| CUSIP Number | 449778109 |
| ISIN Number | US4497781090 |
| Employer ID | 87-0909276 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amy B. Sullivan M.B.A. | Chief Financial Officer |
| Anders Ljungqvist | Founder |
| Daniel G. Mannix Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Faical Miyara Ph.D. | Chief Business Officer |
| Dr. Marjan Shamsaei Pharm.D. | Senior Vice President of Commercial Development & Portfolio Lead |
| Dr. Qasim Iftikhar Ahmad M.D. | Chief Medical Officer |
| Eric Faulkner M.B.A. | Chief Technical Officer |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder & Clinical Advisor |
| Prof. Mads Hald Andersen M.D., Ph.D. | Co-Founder & Scientific Advisor |
| Prof. Per Thor Straten | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 17, 2024 | SC 13D/A | [Amend] Filing |
| Aug 30, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Jul 26, 2024 | 4 | Filing |
| Jun 11, 2024 | 8-K | Current Report |
| Jun 07, 2024 | 4 | Filing |